Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $31.83 Consensus PT from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned an average rating of “Hold” from the nine research firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $34.3333.

A number of equities research analysts recently issued reports on the company. Citigroup raised Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Wedbush reissued a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. HC Wainwright raised Sutro Biopharma from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $10.00 to $28.00 in a report on Tuesday. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Finally, Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective on the stock in a research note on Tuesday, January 20th.

Institutional Investors Weigh In On Sutro Biopharma

Several hedge funds have recently modified their holdings of STRO. Velan Capital Investment Management LP grew its holdings in shares of Sutro Biopharma by 2.0% during the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after buying an additional 60,000 shares in the last quarter. UBS Group AG lifted its stake in shares of Sutro Biopharma by 14.0% during the third quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock valued at $1,602,000 after buying an additional 226,955 shares during the period. AQR Capital Management LLC boosted its position in Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after acquiring an additional 1,206,330 shares during the last quarter. Jane Street Group LLC acquired a new stake in Sutro Biopharma during the second quarter worth approximately $492,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Sutro Biopharma in the 3rd quarter worth approximately $387,000. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma News Summary

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Two analyst upgrades with much higher price targets — HC Wainwright moved from Neutral to Buy and set a $28 target; Wells Fargo upgraded to Overweight with a $27 target — signaling renewed broker confidence and providing fresh buy-side impetus. Article Title
• Positive Sentiment: Pipeline progress: company reported dosing three cohorts in the Phase 1 trial of STRO-004 (TF ADC) and remains on track to report initial clinical data in mid‑2026 — a near‑term binary catalyst that can materially re-rate the stock if data are positive. Article Title
• Neutral Sentiment: Revenue beat: Sutro reported revenue of $11.65M versus analyst expectations of $9.26M, showing commercial or partnership receipts stronger than modeled — a positive data point, but offset by large GAAP losses. Press Release
• Neutral Sentiment: Short-interest data released for March shows zero reported short shares (and nonsensical NaN changes/days-to-cover numbers) — this appears to be a reporting/data issue and should not be interpreted as an actual clean short position. No reliable impact indicated.
• Negative Sentiment: Large EPS miss: Sutro reported a (-$5.39) EPS, missing consensus (-$4.66) by $0.73 and showing a very negative net margin and ROE — a reminder of high burn and continued operating losses that keep dilution risk and financing needs on the table. Press Release

Sutro Biopharma Trading Up 10.5%

Shares of STRO opened at $23.57 on Wednesday. Sutro Biopharma has a 12-month low of $5.23 and a 12-month high of $26.54. The stock has a market cap of $200.58 million, a P/E ratio of -0.90 and a beta of 1.47. The company has a 50-day moving average of $18.39 and a two-hundred day moving average of $12.68.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Monday, March 23rd. The company reported ($5.39) EPS for the quarter, missing the consensus estimate of ($4.66) by ($0.73). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The business had revenue of $11.65 million during the quarter, compared to analyst estimates of $9.26 million. As a group, analysts forecast that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.